The CELsignia Test measured ex vivo real-time live cell response to specific HER family and c-Met agonists to diagnose breast tumors with hyperactive HER1, HER2, HER3, HER4, and c-Met signaling activity. The gene discussed is MET; the disease is breast neoplasm.